This Medical Company Wins Major Lung Cancer Treatment Approval

Apollomics Scores First Approval for Vebreltinib: A Groundbreaking Treatment for Non-Small Cell Lung Cancer.

Global biopharmaceutical company, Apollomics, Inc. has recently announced a significant breakthrough in the fight against non-small cell lung cancer (NSCLC). The company has achieved the first-ever approval of its revolutionary drug, Vebreltinib, specifically designed to treat MET exon 14 skipping NSCLC. This news comes as a beacon of hope for patients …